Eevia Health Plc enters a new stage in global sales project with an international market partner
Eevia Health Plc (”Eevia" or "The Company") has collaborated with a major international ingredient house over the last 12 months on possible commercial cooperation for the global sales of one of Eevia’s ingredients. Following a successful feasibility study conducted by the international partner confirming the ingredient's safety, the project is now progressing to the next stage involving clinical trials, rebranding, and eventual worldwide commercial rollout.
During the last 12 months, the ingredient house has conducted various feasibility investigations for a global launch of a new branded ingredient based on one of Eevia's extracts. These investigations included analytical work and safety studies (toxicology studies), which have provided evidence that the ingredient is safe. The Parties are set to enter into a new phase of collaboration to support the launch of a rebranded product.
The potential partner is a science-oriented global market leader. Eevia has successfully produced multiple industrial-scale batches of the product and provides technical and scientific support to the international partner. With safety studies now completed, the plan is to initiate human clinical research and do a full market launch when the clinical study is completed. In May 2025, our partner will pre-launch a rebranded product in some territories of the global nutraceutical market.
For clarity, this partner and ingredient is not the same as the partner for the eye health product which was communicated in separate press release earlier today.
“This opportunity will provide scientific substantiation on our ingredient funded by our partner and a global sales and distribution reach for this ingredient. The partnership has interesting growth potential for Eevia’s revenues from 2025 onward without major expenses by Eevia in 2024 or 2025. By outsourcing this ingredient's clinical substantiation, marketing, sales, and distribution, Eevia Health can focus its limited resources on other extract products in its portfolio and, for this ingredient, supporting our partner on the supply chain and manufacturing. Our partner will be able to scale up the sales volume of this product, which will benefit our overall revenue growth," says Stein Ulve, Eevia's CEO.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication through the contact person's agency on June 27, 2024, at 12:00 CET.
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
Eevia Health manufactures 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, Chaga mushroom, and pine bark, are wild-harvested sustainably.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.